Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AD Clear all
Withdrawn Phase 1Phase 2 Interventional

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

NCT02961114
View directory record Official record
Conditions
BPH, Nocturia, BPH With Urinary Obstruction, Prostatism, Prostate Inflammation
Interventions
Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline
Procedure · Device · Biological
Lead sponsor
Robert W. Alexander, MD, FICS
Industry
Eligibility
30 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jun 27, 2026, 10:42 AM EDT
Active, not recruiting Phase 2 Interventional

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

NCT03560960
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Effect of Lithium and Divalproex in Alzheimer's Disease

NCT00088387
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Divalproex, Lithium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 27, 2026, 10:42 AM EDT
Recruiting Not applicable Interventional

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

NCT03472664
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
low carbohydrate/high fat diet, low fat/high carbohydrate diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

NCT03817684
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
55 Years to 85 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Gilbert, Arizona • Bellflower, California • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 27, 2026, 10:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting Pre-dementia

NCT07516119
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
Interventions
Not listed
Lead sponsor
Prevention Research Consortium Corp.
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

NCT05189210
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
Drug
Lead sponsor
GemVax & Kael
Industry
Eligibility
55 Years to 85 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD

NCT06803797
View directory record Official record
Conditions
Inactivity, Physical
Interventions
Behavior Change Technique Package
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

NCT04798989
View directory record Official record
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jun 27, 2026, 10:42 AM EDT
Terminated Early Phase 1 Interventional

PET Imaging of Subjects Using 124I-PU-AD

NCT03371420
View directory record Official record
Conditions
Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
Interventions
PU-AD, PET Scan, Blood Draws
Drug · Device · Other
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
21 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.

NCT02185131
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

NCT00003129
View directory record Official record
Conditions
Bladder Cancer
Interventions
valrubicin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
10
States / cities
Tampa, Florida • Urbana, Illinois • East Orange, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

NCT06194552
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NTRX-07, Placebo
Drug
Lead sponsor
NeuroTherapia, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gates Mills, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Jun 27, 2026, 10:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Remotely Delivered Behavioral Weight Loss Using an Ad Libitum Plant-Based Diet Versus a Balanced Calorie Deficit Diet

NCT05337150
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Lifestyle Modification Intervention, Balanced Calorie Deficit Eating Plan, Ad Libitum Whole Food Plant-Based Eating Plan
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Jun 27, 2026, 10:42 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
LY4006895, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Los Alamitos, California • Lady Lake, Florida • Maitland, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Active, not recruiting Early Phase 1 Interventional

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

NCT05469009
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease 1
Interventions
Aducanumab, Exablate Model 4000 Type 2, Lecanemab
Drug · Device
Lead sponsor
Ali Rezai
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jun 27, 2026, 10:42 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Metformin on AD Biomarkers

NCT01965756
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Jun 27, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery

NCT03144921
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Memory Loss
Interventions
psychoeducational skills training intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 27, 2026, 10:42 AM EDT